Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
-1.85% $1.590
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 132.71 mill |
EPS: | -1.730 |
P/E: | -0.920 |
Earnings Date: | May 01, 2024 |
SharesOutstanding: | 83.46 mill |
Avg Daily Volume: | 1.476 mill |
RATING 2024-03-28 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.920 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.16x |
Company: PE -0.920 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.611 (-61.59%) $-0.979 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 1.480 - 1.700 ( +/- 6.92%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-16 | Lieu Hsiao D | Sell | 5 430 | Common Stock |
2024-01-16 | Perlich Irene | Sell | 1 025 | Common Stock |
2024-01-16 | Pierce Valerie L | Sell | 5 021 | Common Stock |
2024-01-16 | Woodhouse David J | Sell | 13 032 | Common Stock |
2023-12-01 | Viret Jean-frederic | Buy | 450 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
20.80 |
Last 100 transactions |
Buy: 7 498 618 | Sell: 3 944 518 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.590 (-1.85% ) |
Volume | 0.357 mill |
Avg. Vol. | 1.476 mill |
% of Avg. Vol | 24.20 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:32 | buy | $1.431 | N/A | Active |
---|
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.